查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971574

慢性病管理市場：依疾病類型、產品類型、服務類型、照護環境、最終使用者和通路分類－全球預測，2026-2032年

Chronic Disease Management Market by Disease Type, Product Type, Service Type, Care Setting, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性病管理市場價值將達到 108.5 億美元，到 2026 年將成長至 116.4 億美元，到 2032 年將達到 194.8 億美元，年複合成長率為 8.71%。

主要市場統計數據
基準年 2025 108.5億美元
預計年份：2026年 116.4億美元
預測年份：2032年 194.8億美元
複合年成長率 (%) 8.71%

簡要概述臨床需求、技術整合和支付方獎勵如何融合以重新定義慢性病管理。

慢性病管理融合了臨床護理、數位化創新和不斷變化的消費者期望，本執行摘要簡要概述了重塑這一領域的各種因素。在整個醫療保健系統中，癌症、心血管疾病、糖尿病和呼吸系統疾病等慢性病需要更整合、持續和以患者為中心的治療方法。護理節奏正從一次性治療轉向強調預防、早期發現、遠端監測和用藥依從性支持的長期參與模式。

以數位化為先導的護理模式、以家庭為基礎的干涉措施以及以結果為導向的契約，是協作重組慢性病管理策略的機制。

慢性病管理領域正經歷著一場獎勵的轉變，其驅動力來自於技術進步、醫療模式的變革以及相關人員的演變。數位健康工具正從輔助實驗室操作轉變為醫療服務的核心要素，從而實現持續監測和主動干預。這種轉變有助於早期發現病情惡化、提高治療依從性，並創建豐富的臨床決策資料集，所有這些都支持更個人化的治療方案製定和風險分層。

美國關稅政策近期變化對整個慢性病照護產品系列。

美國近期關稅政策的變化為慢性病管理相關的供應鏈和成本結構帶來了新的考量。關稅變動影響醫療設備、零件採購和特定療法的經濟效益，進而影響著醫院、診所和經銷商的籌資策略。這些政策轉變促使各方重新評估採購地點，實現供應商多元化，並探索近岸外包或在岸外包方案，從而降低跨境關稅波動帶來的風險。

為了製定目標策略，需要建立詳細的細分框架，將特異性疾病的臨床管道與產品類型、服務模式、分銷管道和護理環境聯繫起來。

細分分析揭示了不同疾病類型、產品類型、服務模式、最終用戶、分銷管道和醫療環境的需求和部署模式的多樣性。這種細分對於制定有針對性的策略至關重要。檢驗疾病類別，我們可以發現癌症、心血管疾病、糖尿病和呼吸系統疾病等目標領域。癌症又可細分為乳癌、大腸癌和肺癌；心血管疾病可分為冠狀動脈疾病、心臟衰竭和高血壓；糖尿病可分為妊娠糖尿病、1 型糖尿病和第 2 型糖尿病；呼吸系統疾病則涵蓋氣喘和慢性阻塞性肺病（COPD）。每個治療領域都有其獨特的臨床管道、監測要求和患者參與需求，這些都會影響診斷方法、醫療設備和治療性介入的選擇。

區域監管差異、支付方結構以及醫療保健基礎設施的差異如何影響全球主要地區的部署管道和商業化重點？

區域趨勢在塑造產品採納曲線、監管複雜性和商業性實施策略方面發揮著至關重要的作用，了解這些差異對於確定優先事項和進入本地市場至關重要。在美洲，完善的報銷系統和成熟的醫療服務提供者網路支援整合設備軟體解決方案的快速擴張。然而，支付方分散以及各州監管法規的細微差異，使得個人化合約和循證方法勢在必行。同時，在美國，市場對利用多元化採購機制和技術的醫療模式有著強烈的需求，同時對可驗證結果和成本降低的監測也日益重視。

永續成長需要展現臨床影響和經濟價值、跨部門夥伴關係以及由產品和服務商品搭售驅動的競爭動態。

慢性病管理領域的競爭行為以跨部門合作、垂直整合以及追求差異化提案主張為特徵，力求在臨床療效和營運效率之間取得平衡。現有醫療設備製造商正拓展其在互聯監測和軟體服務領域的業務能力，利用硬體基礎設施實施循環收入模式和數據驅動的臨床支援。同時，軟體供應商正透過將分析功能整合到電子健康記錄和臨床醫生工作流程中，深化臨床整合，從而提升遠端監測和決策支援工具的臨床效用。

透過互通性、基於證據的價值提案和具有彈性的價值鏈實踐，採取切實可行的策略步驟來加速採用並減少摩擦。

我們針對行業領導者的具體建議強調採取切實可行的步驟，使產品開發、商業策略和營運準備與不斷變化的臨床和支付方期望保持一致。首先，在設備和軟體設計階段優先考慮互通性和基於標準的整合，以創建能夠連接到各種醫療保健IT環境、支援臨床醫生工作流程且無需過度客製化的解決方案。這可以降低採用門檻，並提高整合到機構採購流程中的可能性。

為了檢驗策略結論，我們採用嚴格的混合調查方法，結合對關鍵相關人員的訪談、二級監管和供應鏈分析以及情境測試。

本分析的調查方法整合了基於三角測量法的資訊來源和多方相關人員的意見，以得出可靠且實用的見解。主要研究包括對臨床醫生、採購經理和醫療系統高管進行結構化訪談，以直接了解他們對臨床工作流程、採購決策因素和實施挑戰的看法。此外，還諮詢了技術和治療專家，以了解產品功能、檢驗要求和整合限制，從而補充了這些定性資訊。

整合組織在臨床上整合、實證且商業性永續的慢性病管理解決方案的基本要求。

總之，慢性病管理正處於策略轉折點，技術、臨床實踐和商業模式的整合正在推動更持續、個人化和以結果為導向的醫療服務。成功的機構能夠將臨床洞見轉化為可互通的產品和服務，透過有意義的真實世界結果展現價值，並建立能夠協調醫療服務提供者、保險公司和病患獎勵的商業關係。供應鏈的韌性和快速應對政策變化的能力對於確保產品供應穩定和控制成本壓力同樣至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 慢性病管理市場：依疾病類型分類

  • 癌症
    • 乳癌
    • 結腸癌
    • 肺癌
  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
    • 高血壓
  • 糖尿病
    • 妊娠糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 呼吸系統疾病
    • 氣喘
    • COPD

第9章 慢性病管理市場：依產品類型分類

  • 裝置
    • 管理設備
      • 胰島素幫浦
      • 噴霧器
    • 嵌入式裝置
      • 植入式心臟整流去顫器
      • 心律調節器
    • 監控設備
      • 持續血糖監測
      • 心電圖監測儀
      • 脈搏血氧飽和度分析儀
  • 軟體
    • 分析平台
    • 臨床管理軟體
    • 病人參與工具
  • 治療
    • 生技藥品
    • 非處方藥
    • 處方藥

第10章 慢性病管理市場：依服務類型分類

  • 家庭醫療保健
  • 醫院
  • 門診部
  • 遠端醫療

第11章 慢性病管理市場：依護理環境分類

  • 居家醫療
  • 住院治療
  • 門診治療
    • 門診護理
    • 日托

第12章 慢性病管理市場：依最終用戶分類

  • 診所
  • 診斷中心
  • 家庭醫療保健服務提供者
  • 醫院
  • 病人

第13章 慢性病管理市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第14章 慢性病管理市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 慢性病管理市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 慢性病管理市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國慢性病管理市場

第18章：中國慢性病管理市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Allscripts Healthcare Solutions, Inc.
  • Dexcom, Inc.
  • Epic Systems Corporation
  • Fresenius Medical Care
  • GE HealthCare Technologies Inc.
  • Johnson & Johnson
  • Koninklijke Philips NV
  • Medtronic plc
  • Pegasystems Inc.
  • ResMed Inc.
  • Roche Holding AG
  • Siemens Healthineers AG
Product Code: MRR-535C62918B2F

The Chronic Disease Management Market was valued at USD 10.85 billion in 2025 and is projected to grow to USD 11.64 billion in 2026, with a CAGR of 8.71%, reaching USD 19.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.85 billion
Estimated Year [2026] USD 11.64 billion
Forecast Year [2032] USD 19.48 billion
CAGR (%) 8.71%

A concise orientation to how clinical needs, technology integration, and payer incentives are converging to redefine chronic disease management

Chronic disease management sits at the intersection of clinical care, digital innovation, and shifting consumer expectations, and this executive summary provides a concise synthesis of the forces reshaping the field. Across healthcare systems, chronic conditions such as cancer, cardiovascular disease, diabetes, and respiratory illnesses are demanding more integrated, continuous, and patient-centered approaches. The cadence of care is expanding beyond episodic encounters into longitudinal engagement models that emphasize prevention, early detection, remote monitoring, and adherence support.

Clinicians and health system leaders are increasingly adopting technologies that enable data-driven decision-making and personalized care pathways, while payers are evaluating outcomes-based reimbursement models that reward effective long-term management. As a result, product and service portfolios are evolving to combine devices, software platforms, and therapeutics into cohesive offerings that support clinical workflows and enhance patient experience. This shift is also prompting new commercial arrangements between providers, manufacturers, and technology vendors.

This introduction frames the subsequent analysis by outlining the principal themes that will be explored in depth: the structural shifts in care delivery, the implications of recent tariff policy changes in the United States, nuanced segmentation insights that illuminate demand patterns, regional dynamics that affect adoption and access, and the competitive behaviors that will determine market positioning. The goal is to equip executives and decision-makers with a forward-looking perspective that ties clinical priorities to operational and commercial choices, enabling organizations to act with clarity and purpose.

How digital-first care models, home-based interventions, and performance-focused contracting are jointly reshaping chronic disease management strategies

The landscape of chronic disease management is undergoing transformative shifts driven by technology adoption, changing care paradigms, and evolving stakeholder incentives. Digital health tools have moved from peripheral pilots to core elements of care delivery, enabling continuous monitoring and proactive interventions. This transition is facilitating earlier detection of deterioration, improved adherence to therapeutics, and richer datasets for clinical decision-making, which together support more personalized regimens and risk stratification.

Simultaneously, the locus of care is migrating toward home and community settings as providers and payers seek to reduce avoidable hospitalizations and lower total cost of care. Home-based monitoring and telehealth consultations are becoming standard components of chronic care pathways, requiring devices and software that are interoperable, user-friendly, and validated for clinical use. Interoperability demands and data governance considerations are prompting investments in analytics platforms and clinical management software that can integrate heterogeneous data streams and present actionable insights to clinicians.

On the commercial side, partnerships across device makers, pharmaceutical companies, and technology vendors are deepening, giving rise to bundled solutions that combine therapeutics with connected devices and engagement tools. Regulatory frameworks and reimbursement models are evolving in parallel to accommodate value-based care approaches, creating incentives for demonstrable improvements in outcomes and patient experience. Together, these shifts are reconfiguring competitive dynamics and placing a premium on organizations that can deliver integrated, measurable, and scalable chronic disease management solutions.

Implications of recent United States tariff policy shifts for procurement, supply chain resilience, and commercial strategies across chronic care product portfolios

Recent tariff developments in the United States have introduced new considerations for the supply chains and cost structures underlying chronic disease management. Tariff changes affect the economics of medical devices, component sourcing, and certain therapeutics, which in turn influence procurement strategies across hospitals, clinics, and distributors. These policy shifts create pressure to reassess sourcing footprints, diversify supplier bases, and explore nearshoring or onshoring options to mitigate exposure to cross-border tariff volatility.

Procurement teams and commercial strategists are responding by examining total landed cost, which includes tariff implications, logistics, and inventory carrying expenses. This has led some organizations to favor suppliers with flexible manufacturing footprints and strong contingency plans. In parallel, manufacturers are evaluating the feasibility of adjusting production flows, qualifying alternate component suppliers, and redesigning packaging and distribution approaches to reduce tariff sensitivity.

Beyond procurement, tariff-driven cost pressures can influence strategic pricing, contract negotiations, and channel assortment decisions. Health systems and pharmacy networks may adjust formularies or device preferences based on availability and cost implications, while vendors may look to protect margins through value-added services, subscription models, or bundled offerings that emphasize long-term cost savings. Ultimately, these dynamics underscore the importance of agility and scenario planning in commercial operations to preserve continuity of care and maintain competitive positioning under changing trade regimes.

A detailed segmentation framework that links disease-specific clinical pathways to product categories, service models, distribution routes, and care settings for targeted strategy development

Segmentation analysis reveals the heterogeneity of needs and adoption patterns across disease types, product types, service models, end users, distribution channels, and care settings, and this granularity is essential for designing targeted strategies. When examining disease categories, the landscape spans cancer, cardiovascular disease, diabetes, and respiratory disease, with cancer further disaggregated into breast cancer, colorectal cancer, and lung cancer, cardiovascular disease broken down into coronary artery disease, heart failure, and hypertension, diabetes analyzed across gestational diabetes, type 1 diabetes, and type 2 diabetes, and respiratory disease covering asthma and COPD. Each of these therapeutic areas has distinct clinical pathways, monitoring requirements, and patient engagement needs that influence the choice of diagnostics, devices, and therapeutic interventions.

From a product perspective, chronic disease management combines devices, software, and therapeutics. Devices encompass delivery devices, implantable devices, and monitoring devices, and the delivery subcategory includes insulin pumps and nebulizers, while implantable devices include implantable defibrillators and pacemakers, and monitoring devices include continuous glucose monitors, ECG monitors, and pulse oximeters. Software spans analytics platforms, clinical management software, and patient engagement tools, each playing a different role in data processing, workflow integration, and user interaction. Therapeutics are grouped into biologics, over-the-counter medications, and prescription drugs, and the interactions among these product classes drive the structure of care bundles and commercial offers.

Service type segmentation covers home healthcare, hospital services, outpatient clinics, and telehealth, reflecting the shift toward decentralized care. End users include clinics, diagnostic centers, home healthcare providers, hospitals, and patients themselves, demonstrating how decision-making and purchasing authority are dispersed across clinical and consumer actors. Distribution channels range from hospital pharmacies and online pharmacies to retail and specialty pharmacies, each with unique reimbursement and access dynamics. Care settings are defined as homecare, inpatient, and outpatient, with outpatient further divided into ambulatory care and day care. Understanding these segments in combination allows product developers and commercial teams to tailor value propositions, design reimbursement strategies, and prioritize go-to-market investments according to the clinical workflow and the buyer's needs.

How regional regulatory diversity, payer architectures, and healthcare infrastructure differences shape adoption pathways and commercialization priorities across major global regions

Regional dynamics play a crucial role in shaping adoption curves, regulatory complexity, and commercial execution strategies, and appreciating these differences is vital for prioritization and local market entry. In the Americas, established reimbursement infrastructures and mature provider networks support rapid scaling of integrated device-and-software solutions, though payer fragmentation and state-level regulatory nuances require tailored contracting and evidence-generation approaches. Conversely, the United States presents diverse procurement mechanisms and a strong appetite for technology-enabled care models, but also heightened scrutiny on demonstrable outcomes and cost mitigation.

Europe, Middle East & Africa exhibits wide heterogeneity across national systems, ranging from centralized single-payer contexts that can enable large-scale procurement to fragmented markets where private providers and specialty distributors play outsized roles. Regulatory harmonization efforts in parts of Europe facilitate cross-border commercialization, yet reimbursement timelines and clinical adoption rates vary significantly by country and care setting. The Middle East and Africa region often prioritizes capacity-building and infrastructure investments, creating opportunities for telehealth and portable diagnostics, while also demanding solutions that can operate reliably in diverse environmental and logistical conditions.

Asia-Pacific is characterized by rapid adoption of digital health tools, significant government-backed initiatives to expand home-based care, and an increasing focus on chronic disease prevention and management. Market entry in this region benefits from localized clinical validation, partnerships with domestic manufacturers or distributors, and sensitivity to pricing dynamics and reimbursement pathways that differ markedly between advanced economies and emerging markets. Taken together, these regional insights underscore the need for adaptable commercialization strategies that reconcile global product architectures with local regulatory, clinical, and payer realities.

Competitive dynamics driven by cross-sector partnerships, product-service bundling, and the need to demonstrate clinical impact alongside economic value for sustainable growth

Competitive behavior in chronic disease management is defined by cross-sector collaboration, vertical integration, and the pursuit of differentiated value propositions that align clinical efficacy with operational efficiency. Established device manufacturers are expanding capabilities into connected monitoring and software services, leveraging hardware footprints to introduce recurring revenue models and data-driven clinical support. Meanwhile, software providers are deepening clinical integrations by embedding analytics into electronic health records and clinician workflows, which enhances the clinical utility of remote monitoring and decision-support tools.

Pharmaceutical and biologics companies are increasingly partnering with device and software firms to create combination offerings that pair therapeutics with adherence solutions and monitoring tools, thereby strengthening claims around real-world effectiveness. Service providers and health systems are responding by piloting bundled care pathways that combine medication management, clinical oversight, and patient engagement components to reduce readmissions and improve longitudinal outcomes. New entrants and specialized startups continue to introduce disruptive models focused on niche indications, underserved populations, or novel engagement mechanics, and their agility often accelerates innovation cycles.

Across this competitive landscape, success is driven by the ability to demonstrate clinical impact, interoperability, and scalability, while also proving economic value through reduced resource utilization or improved outcomes. Companies that can translate clinical data into compelling payer propositions, and then operationalize those propositions through robust implementation support and clinician training, will be best positioned to capture long-term partnerships with providers and payers.

Practical strategic steps for leaders to accelerate adoption and reduce friction through interoperability, evidence-based value propositions, and resilient supply chain practices

Actionable recommendations for industry leaders emphasize pragmatic steps to align product development, commercial strategy, and operational readiness with evolving clinical and payer expectations. First, prioritize interoperability and standards-based integration when designing devices and software so that solutions can plug into diverse health IT environments and support clinician workflows without requiring extensive customization. This reduces adoption friction and increases the likelihood of inclusion in institutional procurement processes.

Second, design evidence-generation programs that go beyond traditional clinical endpoints to include real-world operational metrics such as adherence, hospitalization rates, and caregiver burden. These outcomes are often central to payer discussions and provider adoption decisions, and they enable stronger value narratives. Third, diversify supply chain strategies to mitigate tariff and logistics risks by qualifying alternate suppliers, exploring regional manufacturing partnerships, and maintaining inventory buffers for critical components.

Fourth, adopt flexible commercial models that align incentives across stakeholders, including subscription services, outcome-based contracts, and bundled offerings that combine therapeutics, devices, and support services. Fifth, invest in clinician and patient education programs that lower barriers to effective use and sustain engagement over time. Finally, localize market entry strategies by aligning regulatory and reimbursement evidence with regional priorities, and consider partnering with trusted local distributors or clinical networks to accelerate adoption and scale.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary regulatory and supply chain analysis, and scenario testing to validate strategic conclusions

The research methodology underpinning this analysis integrates triangulated sources and multi-stakeholder inputs to produce robust, actionable insights. Primary research included structured interviews with clinicians, procurement leaders, and health system executives to capture firsthand perspectives on clinical workflows, purchasing decision drivers, and implementation challenges. These qualitative inputs were complemented by expert consultations with technology and therapeutics specialists to understand product capabilities, validation needs, and integration constraints.

Secondary analysis incorporated regulatory documentation, clinical guidelines, and publicly available policy announcements to contextualize the operational and reimbursement environment in key regions. Trade and supply chain data were examined to identify persistent vulnerabilities and to map supplier footprints relevant to device and component sourcing. The methodology emphasized cross-validation of findings across these inputs to reduce bias and ensure that strategic recommendations are grounded in observable trends rather than isolated anecdotes.

Finally, scenario analysis was employed to stress-test strategic choices under different policy and economic conditions, enabling the identification of resilient pathways for commercialization and clinical deployment. This mixed-method approach ensures that the conclusions drawn reflect both front-line operational realities and systemic forces influencing chronic disease management.

A synthesis of essential imperatives for organizations to scale clinically integrated, evidence-backed, and commercially sustainable chronic disease management solutions

In conclusion, chronic disease management is at a strategic inflection point where technology, clinical practice, and commercial models are converging to enable more continuous, personalized, and outcome-focused care. Organizations that succeed will be those that translate clinical insights into interoperable products and services, demonstrate value through meaningful real-world outcomes, and structure commercial relationships that align incentives across providers, payers, and patients. Resilience in supply chains and agility in response to policy shifts are equally important to sustain product availability and manage cost pressures.

The interplay between disease-specific clinical pathways and product-service configurations underscores the need for nuanced segmentation and tailored go-to-market strategies. Regional differences in regulation, payer behavior, and infrastructure require adaptive commercialization plans that reconcile global product capabilities with local requirements. Competitive advantage will accrue to entities that can operationalize cross-sector partnerships, deploy rigorous evidence-generation programs, and support adoption through clinician and patient education.

Taken together, these insights provide a blueprint for action: invest in integration and evidence, protect supply chains, and align commercial models to the realities of care delivery. Doing so will position organizations to improve patient outcomes, strengthen economic sustainability, and scale impactful chronic disease management solutions across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Disease Management Market, by Disease Type

  • 8.1. Cancer
    • 8.1.1. Breast Cancer
    • 8.1.2. Colorectal Cancer
    • 8.1.3. Lung Cancer
  • 8.2. Cardiovascular Disease
    • 8.2.1. Coronary Artery Disease
    • 8.2.2. Heart Failure
    • 8.2.3. Hypertension
  • 8.3. Diabetes
    • 8.3.1. Gestational Diabetes
    • 8.3.2. Type 1 Diabetes
    • 8.3.3. Type 2 Diabetes
  • 8.4. Respiratory Disease
    • 8.4.1. Asthma
    • 8.4.2. Copd

9. Chronic Disease Management Market, by Product Type

  • 9.1. Devices
    • 9.1.1. Delivery Devices
      • 9.1.1.1. Insulin Pumps
      • 9.1.1.2. Nebulizers
    • 9.1.2. Implantable Devices
      • 9.1.2.1. Implantable Defibrillators
      • 9.1.2.2. Pacemakers
    • 9.1.3. Monitoring Devices
      • 9.1.3.1. Continuous Glucose Monitors
      • 9.1.3.2. Ecg Monitors
      • 9.1.3.3. Pulse Oximeters
  • 9.2. Software
    • 9.2.1. Analytics Platforms
    • 9.2.2. Clinical Management Software
    • 9.2.3. Patient Engagement Tools
  • 9.3. Therapeutics
    • 9.3.1. Biologics
    • 9.3.2. Otc Drugs
    • 9.3.3. Prescription Drugs

10. Chronic Disease Management Market, by Service Type

  • 10.1. Home Healthcare
  • 10.2. Hospital
  • 10.3. Outpatient Clinic
  • 10.4. Telehealth

11. Chronic Disease Management Market, by Care Setting

  • 11.1. Homecare
  • 11.2. Inpatient
  • 11.3. Outpatient
    • 11.3.1. Ambulatory Care
    • 11.3.2. Day Care

12. Chronic Disease Management Market, by End User

  • 12.1. Clinics
  • 12.2. Diagnostic Centers
  • 12.3. Home Healthcare Providers
  • 12.4. Hospitals
  • 12.5. Patients

13. Chronic Disease Management Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy
  • 13.4. Specialty Pharmacy

14. Chronic Disease Management Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Chronic Disease Management Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Chronic Disease Management Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Chronic Disease Management Market

18. China Chronic Disease Management Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Allscripts Healthcare Solutions, Inc.
  • 19.7. Dexcom, Inc.
  • 19.8. Epic Systems Corporation
  • 19.9. Fresenius Medical Care
  • 19.10. GE HealthCare Technologies Inc.
  • 19.11. Johnson & Johnson
  • 19.12. Koninklijke Philips N.V.
  • 19.13. Medtronic plc
  • 19.14. Pegasystems Inc.
  • 19.15. ResMed Inc.
  • 19.16. Roche Holding AG
  • 19.17. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CHRONIC DISEASE MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CHRONIC DISEASE MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEFIBRILLATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEFIBRILLATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEFIBRILLATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PACEMAKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PACEMAKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ECG MONITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ECG MONITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ECG MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PULSE OXIMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PULSE OXIMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PULSE OXIMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ANALYTICS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ANALYTICS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ANALYTICS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CLINICAL MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CLINICAL MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CLINICAL MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PATIENT ENGAGEMENT TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PATIENT ENGAGEMENT TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PATIENT ENGAGEMENT TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OTC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OTC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TELEHEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DAY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DAY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DAY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOME HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOME HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOME HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY RESPIRATORY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET SIZE, BY